Comparison of Industry and National Institutes of Health Funding for Orthopedic Surgery Research.

IF 1.2 4区医学 Q3 ORTHOPEDICS

Orthopedics Pub Date : 2025-07-01 Epub Date: 2025-07-16 DOI:10.3928/01477447-20250625-01

Mitchell K Ng, Pedro Rullan-Oliver, Matthew Magruder, Paul G Mastrokostas, Viktor E Krebs, Javad Parvizi, Michael A Mont, Nicolas S Piuzzi

{"title":"Comparison of Industry and National Institutes of Health Funding for Orthopedic Surgery Research.","authors":"Mitchell K Ng, Pedro Rullan-Oliver, Matthew Magruder, Paul G Mastrokostas, Viktor E Krebs, Javad Parvizi, Michael A Mont, Nicolas S Piuzzi","doi":"10.3928/01477447-20250625-01","DOIUrl":null,"url":null,"abstract":"Background: The aims of this study were to analyze trends in National Institutes of Health (NIH) funding for musculoskeletal (MSK) research from 2012 to 2021, compare private industry funding to NIH funding, determine the proportion of total MSK research funding from public versus private sources, and examine how private industry research and development (R&D) spending has evolved in relation to net sales.Materials and methods: Public research funding from 2012 to 2021 was aggregated using NIH data for MSK conditions with >$10M in funding. Private R&D funding was obtained from the top five orthopedic companies by revenue and compared to net sales to calculate R&D as a percentage of total sales. Annually reported financial statements from Securities Exchange Commission filings were used. Private funding was summed annually and compared to National Institute of Arthritis and Musculoskeletal and Skin Diseases spending using descriptive statistics.Results: Annual research funding from the top five orthopedic companies is 10.0 times that of the NIH, an increase from 9.2 times in 2017. The top five companies spent a mean of 7.2% of their net sales on R&D. Overall, $7.7 billion is allocated to MSK research annually, with only 9.1% from public sources.Conclusion: Given this disparity, efforts should assess public investment in orthopedic research while recognizing the critical role of industry in funding musculoskeletal research. [Orthopedics. 2025;48(4):e182-e186.].","PeriodicalId":19631,"journal":{"name":"Orthopedics","volume":"48 4","pages":"e182-e186"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopedics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/01477447-20250625-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aims of this study were to analyze trends in National Institutes of Health (NIH) funding for musculoskeletal (MSK) research from 2012 to 2021, compare private industry funding to NIH funding, determine the proportion of total MSK research funding from public versus private sources, and examine how private industry research and development (R&D) spending has evolved in relation to net sales.

Materials and methods: Public research funding from 2012 to 2021 was aggregated using NIH data for MSK conditions with >$10M in funding. Private R&D funding was obtained from the top five orthopedic companies by revenue and compared to net sales to calculate R&D as a percentage of total sales. Annually reported financial statements from Securities Exchange Commission filings were used. Private funding was summed annually and compared to National Institute of Arthritis and Musculoskeletal and Skin Diseases spending using descriptive statistics.

Results: Annual research funding from the top five orthopedic companies is 10.0 times that of the NIH, an increase from 9.2 times in 2017. The top five companies spent a mean of 7.2% of their net sales on R&D. Overall, $7.7 billion is allocated to MSK research annually, with only 9.1% from public sources.

Conclusion: Given this disparity, efforts should assess public investment in orthopedic research while recognizing the critical role of industry in funding musculoskeletal research. [Orthopedics. 2025;48(4):e182-e186.].

查看原文本刊更多论文

工业与国立卫生研究院骨科外科研究经费之比较。

背景：本研究的目的是分析2012年至2021年美国国立卫生研究院（NIH）对肌肉骨骼（MSK）研究的资助趋势，比较私人行业资助与NIH资助，确定公共与私人来源的MSK研究资金总额的比例，并研究私营行业研究与开发（R&D）支出与净销售额的关系。材料和方法：2012年至2021年的公共研究资金使用NIH数据汇总MSK条件，资金为1000万美元。私人研发资金来自收入排名前五的骨科公司，并与净销售额进行比较，以计算研发占总销售额的百分比。采用了美国证券交易委员会（sec）提交的年度财务报表。每年汇总私人资金，并使用描述性统计将其与国家关节炎、肌肉骨骼和皮肤疾病研究所的支出进行比较。结果：前五大骨科公司的年度研究经费是NIH的10.0倍，高于2017年的9.2倍。排名前五的公司平均将其净销售额的7.2%用于研发。总的来说，每年有77亿美元用于MSK研究，其中只有9.1%来自公共资源。结论：鉴于这种差异，我们应该努力评估骨科研究的公共投资，同时认识到工业在资助肌肉骨骼研究方面的关键作用。[矫形手术。48 2025; (4): e182-e186。]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Orthopedics 医学-整形外科

CiteScore

2.20

自引率

0.00%

发文量

160

审稿时长

3 months

期刊介绍： For over 40 years, Orthopedics, a bimonthly peer-reviewed journal, has been the preferred choice of orthopedic surgeons for clinically relevant information on all aspects of adult and pediatric orthopedic surgery and treatment. Edited by Robert D''Ambrosia, MD, Chairman of the Department of Orthopedics at the University of Colorado, Denver, and former President of the American Academy of Orthopaedic Surgeons, as well as an Editorial Board of over 100 international orthopedists, Orthopedics is the source to turn to for guidance in your practice. The journal offers access to current articles, as well as several years of archived content. Highlights also include Blue Ribbon articles published full text in print and online, as well as Tips & Techniques posted with every issue.